MAIA-2022-12 / MAIA Biotech - LARVOL DELTA

MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy (Businesswire) - "MAIA Biotechnology...announced the publication of preclinical data from its second generation ateganosine prodrugs platform in Nucleic Acids Research (NAR), a leading open-access peer-reviewed scientific journal. The study, titled 'Novel Telomere-Targeting Dual-Pharmacophore Dinucleotide Prodrugs for Anticancer Therapy,' details MAIA’s lead ateganosine (THIO)-derived second-generation prodrugs as promising new molecules in its strategy for enhancing cancer treatment and overcoming drug resistance....The lead THIO-containing compounds, with two THIO pharmacophores, demonstrated the strongest anticancer efficacy in vivo and induced the strongest host immune-memory responses in vivo. 'The reported study data has shown that the sequential combination of MAIA-2022-12 or MAIA-2021-20 with an immune checkpoint inhibitor demonstrated a significantly lower 50% inhibitory concentration with superior anticancer efficacy compared with the corresponding monotherapies'."

Preclinical • Oncology

Novel telomere-targeting dual-pharmacophore dinucleotide prodrugs for anticancer therapy. (PubMed, Nucleic Acids Res) - "We designed and synthesized divalent dinucleotide prodrugs comprised of 6-thio-2'-deoxyguanosine (6-thio-dG; THIO) and 5-fluoro-2'-deoxyuridine (5-FdU) nucleosides. The sequential combination of MAIA-2022-12 or MAIA-2021-20 with the immune anti-PD-1 or anti-PD-L1 checkpoint inhibitors demonstrated superior anticancer efficacy compared with the corresponding monotherapies. We conclude that MAIA-2022-12 and MAIA-2021-20 are promising candidates for future preclinical and potential clinical studies."

IO biomarker • Journal • Oncology

New dual-pharmacophore dinucleotide prodrugs as potent telomere targeting anticancer molecules (EORTC-NCI-AACR 2024) - "The nucleoside analogue THIO (6-thio-2'-deoxyguanosine, a.k.a 6-thio-dG; 6SdG) is a first-in-class telomerase-mediated telomere-targeting anticancer agent currently undergoing Phase II clinical trials for the treatment of immune checkpoint inhibitors resistant non-small cell lung cancer (NSCLC) patients. The obtained data for the new prodrug divalent dinucleotides MAIA-2022-12 and MAIA-2021-20 provide rationale for their further detailed preclinical studies in different cancer type models."

IO biomarker • Colorectal Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor

MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics (Businesswire) - "MAIA Biotechnology, Inc.announced that an abstract related to the company’s second generation of proprietary telomere-targeting THIO prodrugs has been accepted for poster presentation during the upcoming 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place October 23-25, 2024, in Barcelona, Spain....MAIA will present the results of preclinical studies for its new THIO-based prodrugs, designated as MAIA-2021-20 and MAIA-2022-12, which are lipid-conjugated compounds derived from THIO."

Preclinical • Oncology